Biggest News Aggregation in the World
๐Ÿ“ฐ Proffered Paper News

Page 2 - Proffered Paper News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Proffered Paper. Real-time updates on events, politics, business and more.

Menarini Industrie Farmaceutiche Riunite: Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a
United States Elcin Barker Ergun Breast Cancer Congress Menarini Group American Society Of Clinical Oncology Stemline Therapeutics Inc

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2...
Chuck Baum Prnewswire Mirati Therapeutics Inc Mirati Therapeutics Inc Exchange Commission Oncology Esmo Io Congress Oncology Annual Congress

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2...
Chuck Baum Prnewswire Mirati Therapeutics Inc Mirati Therapeutics Inc Exchange Commission Oncology Esmo Io Congress Oncology Annual Congress

Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022

/PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes...
Xiaoyan Kang Sasia Congress European Society For Medical Oncology Qilu Pharmaceutical Co Ltd Active Pharmaceutical Ingredients Proffered Paper

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

– DCC-3116 Was Well-tolerated with No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events Observed – – Pharmacokinetic and Pharmacodynamic Data Across all Doses... | September 10, 2022
United States Hong Kong United Kingdom Matthewl Sherman Anthony Tolcher Deciphera Pharmaceuticals

F. Hoffmann-La Roche Ltd: New data from the phase II CITYSCAPE trial show encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free
United States Nathalie Meetz Levi Garraway Karl Mahler Sabine Borngr Gerard Tobin

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science